A phase 1/2 trial of enzastaurin and erlotinib in patients with advanced solid tumors and non-small cell lung cancer (NSCLC) after prior chemotherapy.
Phase of Trial: Phase I/II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Enzastaurin; Erlotinib
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 30 Nov 2016 Status changed from active, no longer recruiting to completed.
- 01 Nov 2013 Planned end date changed from 1 Sep 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
- 12 Jun 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.